Nod for vaccine development

The A(H1N1) influenza vaccine will be prioritized to ensure fast development and quality control ahead of its likely entry into the Chinese market at the end of July.

The State Food and Drug Administration (SFDA) said it would shorten the regular waiting time for domestic vaccine producers to receive a production pass.

However, that did not mean it would skip measures that ensure the safety and efficacy of the coming vaccine, spokesperson Yan Jiangying said yesterday at the monthly press conference